Cancer immunotherapy

Bio-Techne Announces Licensing of Proprietary Antibody to Xencor for Therapeutic Development

Wednesday, April 14, 2021 - 12:00pm

This is Bio-Techne\'s third licensing agreement with Xencor, a leader in protein engineering in the immuno-oncology field.

Key Points: 
  • This is Bio-Techne\'s third licensing agreement with Xencor, a leader in protein engineering in the immuno-oncology field.
  • Under the terms of this agreement, Bio-Techne grants Xencor access to a proprietary Bio-Techne antibody for use with their proprietary XmAb protein engineering technology, which is revolutionizing the development of new cancer therapeutics such as bispecific antibodies and engineered cytokines.\n"We are extremely excited about this agreement with Xencor.
  • Our goal for antibody development is to create highly specific antibodies against important therapeutic targets.
  • "We are proud of our long history of being the partner of choice for therapeutic antibody discovery and our innovative antibody discovery platform that is harnessed by our pharma customers to fast-track their therapeutic programs.

GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021

Wednesday, April 14, 2021 - 7:54am

As aninnate immunestimulator, TLR9 agonist canbecombined with checkpoint inhibitors to increase itsanti-tumor effects.

Key Points: 
  • As aninnate immunestimulator, TLR9 agonist canbecombined with checkpoint inhibitors to increase itsanti-tumor effects.
  • Local injection of the TLR9 agonist is well-tolerated but the drug can degrade in the local tissues or dissipate from the site of action rapidly, resulting in reducedefficacy.
  • GeneLeap\'s researchers have conducted preclinical studies in a mouse tumor model to examine whether a single dose of Hydrogel encapsulated TLR9 agonist can be effective over a longer period in immune activation without toxicity.\nThe current preclinical study showed that a single administration of hydrogel encapsulated TLR9 agonist demonstrates tumor growth inhibition and non-toxicity similar to that of a multiple dose of TLR9 agonist without hydrogel encapsulation.
  • This indicates that for those patients who are resistant or refractory to checkpoint inhibitors, hydrogel encapsulated TLR9 agonist could enhance the immune response to checkpoint inhibitors for a longer time.

AmunBio and NorthShore University HealthSystem to Advance Cancer Immunotherapy with Next Generation Engineered Oncolytic Viruses

Tuesday, April 13, 2021 - 12:00pm

The development of oncolytic viral therapies, which represents a unique therapeutic paradigm within Immuno-Oncology, is gaining momentum.

Key Points: 
  • The development of oncolytic viral therapies, which represents a unique therapeutic paradigm within Immuno-Oncology, is gaining momentum.
  • This technology forms the core of AmunBio\'s proprietary, multimodal therapeutic approach utilizing direct destruction of cancer cells and immune system activation.
  • AMUN-003 can be administered both locally as well as systemically.\nPreclinical studies with AMUN-003 in breast cancer alone, compared to prior oncolytic virus constructs, demonstrated near-complete breast cancer inhibition.
  • With the novel, next-generation, proprietary technology platform approach, utilizing direct destruction of cancer cells and immune system activation, patients will be uniquely positioned to defeat cancer.

Alliance for Cancer Gene Therapy Summit 2021 Features World Renowned Cancer Researchers Advancing Solid Tumor Breakthroughs

Friday, April 16, 2021 - 2:00pm

The scientists and companies driving the latest advances in cancer cell and gene therapy will gather online for a virtual Summit with the Alliance for Cancer Gene Therapy, who envision a cancer free future and want to change the C-word from Cancer to Cure.

Key Points: 
  • The scientists and companies driving the latest advances in cancer cell and gene therapy will gather online for a virtual Summit with the Alliance for Cancer Gene Therapy, who envision a cancer free future and want to change the C-word from Cancer to Cure.
  • The Summit is open to the public, to medical professionals, scientists and companies interested in cell and gene therapy to fight cancer.
  • Alliance for Cancer Gene Therapy funds researchers who are pioneering the potential of cancer cell and gene therapy talented visionaries whose scientific advancements are driving the development of groundbreaking treatments for ovarian, prostate, sarcoma, glioblastoma, melanoma and pancreatic cancers.
  • For more information, visit acgtfoundation.org , call 203-358-5055, or join the Alliance for Cancer Gene Therapy community on Facebook , Twitter , LinkedIn , Instagram and YouTube @acgtfoundation.\n'

Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™

Saturday, April 10, 2021 - 6:31pm

The presentations featured studies of Oncocytes novel predictor of immunotherapy response, DetermaIO, demonstrating test performance in bladder cancer, now the third cancer type, suggesting potential applicability across multiple cancer types.

Key Points: 
  • The presentations featured studies of Oncocytes novel predictor of immunotherapy response, DetermaIO, demonstrating test performance in bladder cancer, now the third cancer type, suggesting potential applicability across multiple cancer types.
  • At the conference, Oncocyte debuted data in bladder cancer in two studies, including one highlighted in a podium presentation.
  • Taken together, these data support the potential use of the 27-gene DetermaIO test as a pan-cancer predictor of response to ICI therapy.
  • These statements include those pertaining to the data presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, the potential use of DetermaIO across multiple tumor types, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management.

Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1

Saturday, April 10, 2021 - 1:30pm

The Company believes these data further support the potential for INTASYL mPH-762 to provide strong local immune checkpoint blockade (ICB), without the dose immune-related adverse effects (irAEs) seen with systemic ICB antibody therapy.

Key Points: 
  • The Company believes these data further support the potential for INTASYL mPH-762 to provide strong local immune checkpoint blockade (ICB), without the dose immune-related adverse effects (irAEs) seen with systemic ICB antibody therapy.
  • "We are pleased to announce new in vivo data today that show INTASYL mPH-762 offered strong tumor control in Hepa 1-6 and CT26 models, which are PD-1 responsive and PD-1 refractory models, respectively.
  • "These data further support our excitement around this asset andto bring PH-762 to patients, starting with our first clinical study later this year."
  • Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL) therapeutic platform.

Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021

Saturday, April 10, 2021 - 1:30pm

SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the availability of three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the availability of three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting.
  • ET through the virtual meeting website at www.aacr.org and on the Harpoon corporate website at www.harpoontx.com .
  • Data show that FLT3 TriTACs bind human and non-human primate FLT3, and can redirect T cells to kill FLT3 expressing cells in vitro.
  • These forward-looking statements are based on Harpoon Therapeutics expectations and assumptions as of the date of this press release.

iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021

Saturday, April 10, 2021 - 1:30pm

The presentation highlights initial findings from the completed dose escalation monotherapy portion of the trial, indicating a favorable tolerability profile and early signs of clinical activity in advanced cancers.

Key Points: 
  • The presentation highlights initial findings from the completed dose escalation monotherapy portion of the trial, indicating a favorable tolerability profile and early signs of clinical activity in advanced cancers.
  • We are pleased to share these data showing promising preliminary signs of clinical activity and a favorable tolerability profile with our anti-TIGIT antibody, EOS-448, in patients with advanced cancers, said Joanne Jenkins Lager, M.D., chief medical officer of iTeos Therapeutics.
  • Since the data cut-off for the AACR poster, as of March 9, 2021, an additional 11 patients have received single agent EOS-448.
  • Preliminary evidence of clinical activity as a monotherapy, including a confirmed partial response in one pembrolizumab-refractory melanoma patient and disease stabilization in nine patients, was also observed.

New Clinical Responses for AGEN1181 Presented at AACR

Saturday, April 10, 2021 - 1:35pm

AGEN1181 is showing activity in patients with tumors which typically do not respond to first-generation CTLA-4 and PD-1 antibodies.

Key Points: 
  • AGEN1181 is showing activity in patients with tumors which typically do not respond to first-generation CTLA-4 and PD-1 antibodies.
  • In two separate presentations at AACR, Agenus showcased the optimal performance of AGEN1181 in relevant models.
  • In addition, as the clinical data matures, additional responses as well as a conversion from a partial response to a complete response, have been observed.
  • The new data announced today include the following clinical responses:
    E-poster presentations were made available on the conference platform on April 10 at 8:30am ET.

Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021

Saturday, April 10, 2021 - 1:30pm

CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new insights into Inhibigen-associated responses and continues to underscore the detrimental impact of their inclusion in cancer immunotherapies at theAmerican Association for Cancer Research (AACR) Annual Meeting 2021 fromApril 10-15.

Key Points: 
  • CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new insights into Inhibigen-associated responses and continues to underscore the detrimental impact of their inclusion in cancer immunotherapies at theAmerican Association for Cancer Research (AACR) Annual Meeting 2021 fromApril 10-15.
  • The combination of this single Inhibigen with the otherwise-protective vaccine abrogated vaccine efficacy and returned tumor growth to levels of unvaccinated mice.
  • Our data add to a growing body of preclinical and clinical evidence confirming thatInhibigensare not innocent bystanders, butrathertheycan reverse the beneficial effects of cancer immunotherapies, said Hanna Starobinets, a scientist at Genocea and lead presenter at the AACR meeting.
  • While Genocea continues to exclude Inhibigens from its immunotherapy candidates, ongoing studies aim to further allow us to understand and overcome immunotherapy resistance.